<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04352413</url>
  </required_header>
  <id_info>
    <org_study_id>HE071-CSP-010</org_study_id>
    <nct_id>NCT04352413</nct_id>
  </id_info>
  <brief_title>A Study of PLM60 in Subjects With Relapsed Small-cell Lung Cancer After Platinum-based First-Line Chemotherapy</brief_title>
  <official_title>An Open-label, Multi-center, Phase 2 Study of Liposome-entrapped Mitoxantrone Hydrochloride Injection (PLM60) in Subjects With Relapsed Small-cell Lung Cancer After Platinum-based First-Line Chemotherapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>CSPC ZhongQi Pharmaceutical Technology Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>CSPC ZhongQi Pharmaceutical Technology Co., Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an open, multicenter phase II clinical study for PLM60. The primary aim of the study
      is to observe the initial efficacy of PLM60 in treatment of small cell lung cancer. The
      secondary aim is to explore the safety and PK characteristics of PLM60
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">May 31, 2020</start_date>
  <completion_date type="Anticipated">January 30, 2022</completion_date>
  <primary_completion_date type="Anticipated">January 30, 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Objective response rate (ORR)</measure>
    <time_frame>Through study completion, an average of 2 year</time_frame>
    <description>To evaluate ORR in SCLC subjects treated with PLM60</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Duration of Response (DoR)</measure>
    <time_frame>Through study completion, an average of 2 year</time_frame>
    <description>To evaluate DoR in SCLC subjects treated with PLM60</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease Control Rate (DCR)</measure>
    <time_frame>Through study completion, an average of 2 year</time_frame>
    <description>To evaluate DCR in SCLC subjects treated with PLM60</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression Free Survival (PFS)</measure>
    <time_frame>Through study completion, an average of 2 year</time_frame>
    <description>To evaluate PFS in SCLC subjects treated with PLM60</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS)</measure>
    <time_frame>Through study completion, an average of 2 year</time_frame>
    <description>To evaluate OS in SCLC subjects treated with PLM60</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse Events</measure>
    <time_frame>Through study completion, an average of 2 year</time_frame>
    <description>To evaluate the safety profiles in SCLC subjects treated with PLM60</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serious Adverse Events (SAEs)</measure>
    <time_frame>Through study completion, an average of 2 year</time_frame>
    <description>To evaluate the safety profiles in SCLC subjects treated with PLM60</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">81</enrollment>
  <condition>Small Cell Lung Cancer</condition>
  <arm_group>
    <arm_group_label>Cohort A: PLM60</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>20 mg/m2, 4 weeks/cycle, administered on day 1 of each cycle</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort B: PLM60</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>15mg/m2, 3 weeks/cycle, administered on day 1 of each cycle</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PLM60</intervention_name>
    <description>Administration: Intravenous infusion</description>
    <arm_group_label>Cohort A: PLM60</arm_group_label>
    <arm_group_label>Cohort B: PLM60</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Histologically confirmed diagnosis of SCLC;

          2. Must have recurrence or progression after platinum-based first-line chemotherapy or
             chemoradiation therapy for the treatment of SCLC;

          3. ECOG performance status 0~2;

          4. Measurable lesion according to RECIST v1.1;

          5. Life expectancy ≥ 12 weeks;

          6. Adequate organ function;

          7. Signed informed consent from the patient.

        Exclusion Criteria:

          1. Radical surgical treatment for primary small cell lung cancer;

          2. Any anti-tumor treatment received within 4 weeks before the first use of the study
             drug;

          3. Untreated or symptomatic central nervous system (CNS) metastases;

          4. Uncontrolled pleural effusion, pericardial effusion, or ascites requiring repeated
             drainage;

          5. History of serious systemic diseases;

          6. History of serious autoimmune diseases;

          7. Those receiving treatment of adriamycin or other anthracyclines previously, with the
             total cumulative adriamycin (or adriamycin-equivalent) dose of ＞360 mg/m2.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kun Lou</last_name>
    <role>Study Chair</role>
    <affiliation>Department of Medicine, CSPC Clinical Development Division</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Kun Lou</last_name>
    <phone>0311-67808817</phone>
    <email>loukun@mail.ecspc.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Xuefang Xia</last_name>
    <phone>010-63930702</phone>
    <email>xiaxuefang@mail.ecspc.com</email>
  </overall_contact_backup>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>April 14, 2020</study_first_submitted>
  <study_first_submitted_qc>April 15, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">April 20, 2020</study_first_posted>
  <last_update_submitted>April 15, 2020</last_update_submitted>
  <last_update_submitted_qc>April 15, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 20, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Small Cell Lung Carcinoma</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

